Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Drugs Aging. 2012 Jun 1;29(6):427-34. doi: 10.2165/11633520-000000000-00000.

Off-label prescribing in older patients.

Author information

  • 1Department of Clinical Gerontology, Kings Health Partners Academic Health Science Centre, London, UK. stephen.jackson@kcl.ac.uk

Abstract

The practice of off-label prescribing, i.e. prescribing drugs either for unregistered/unapproved therapeutic indications and age groups or using unregistered/unapproved doses or methods of administration, is common in older patients. This may be due to the poor representation of this group in pre-marketing clinical trials assessing therapeutic efficacy and safety of novel therapies or merely to the fact that trials in a particular indication have not been undertaken. Off-label prescribing should not be viewed as scientifically or ethically unsound when there are good clinical data to support a particular therapeutic indication. However, a number of steps should be followed in order to ensure therapeutic efficacy, reducing, at the same time, the risk of adverse drug reactions and/or medical litigation. This article discusses the current epidemiology and trends in off-label prescribing in older patients, the scientific and ethical justification of this practice, medico-legal implications, and proposed strategies for risk mitigation.

Comment in

PMID:
22642777
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk